Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum APC1472
- Development stage
- Preclinical
- Lead developer
- APC Microbiome
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum APC1472 is an investigational live biotherapeutic product (probiotic) being developed for the management of obesity and related metabolic conditions. It is a specific strain of *Bifidobacterium longum* that was initially selected for its ability to attenuate ghrelin receptor signaling in vitro. [1] Preclinical studies in mice showed that it reduced body weight gain, fat accumulation, and improved glucose tolerance. [3] A clinical study in overweight and obese humans (NCT04042181) did not show a significant effect on the primary endpoint of BMI, but did demonstrate a statistically significant reduction in fasting blood glucose levels compared to placebo. [1, 3] In a sub-analysis of obese participants, it also increased active ghrelin levels and reduced the cortisol awakening response, suggesting modulation of the ghrelinergic system and the hypothalamic-pituitary-adrenal (HPA) axis. [2, 5]
02
Targets
GHSR (Growth hormone secretagogue receptor)
Beyond the preview
Go deeper on Bifidobacterium longum APC1472.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum APC1472.